Therapeutic potential of Toll-like receptor 9 activation (original) (raw)

• Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nature Immunol. 5, 987–995 (2004).
  Article CAS Google Scholar
• Barton, G. M., Kagan, J. C. & Medzhitov, R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nature Immunol. 7, 49–56 (2006). This report demonstrates that the ability of TLR9 to detect specifically viral but not self DNA is a consequence of TLR9's unusual intracellular localization.
  Article CAS Google Scholar
• Ishii, K. J. et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nature Immunol. 7, 40–48 (2006).
  Article CAS Google Scholar
• Okabe, Y., Kawane, K., Akira, S., Taniguchi, T. & Nagata, S. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J. Exp. Med. 202, 1333–1339 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, Y. J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275–306 (2005).
  Article CAS PubMed Google Scholar
• Hayashi, F., Means, T. K. & Luster, A. D. Toll-like receptors stimulate human neutrophil function. Blood 102, 2660–2669 (2003).
  Article CAS PubMed Google Scholar
• Li, J. et al. CpG DNA-mediated immune response in pulmonary endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 287, L552–L558 (2004).
  Article CAS PubMed Google Scholar
• Platz, J. et al. Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J. Immunol. 173, 1219–1223 (2004).
  Article CAS PubMed Google Scholar
• Asselin-Paturel, C. et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 201, 1157–1167 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709–760 (2002).
  Article CAS PubMed Google Scholar
• Jung, J. et al. Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J. Immunol. 169, 2368–2373 (2002).
  Article CAS PubMed Google Scholar
• Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199–2202 (2002).
  Article CAS PubMed Google Scholar
• Bernasconi, N. L., Onai, N. & Lanzavecchia, A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101, 4500–4504 (2003).
  Article CAS PubMed Google Scholar
• Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Med. 10, 871–875 (2004). Building on their earlier studies (references 12 and 13) into the ability of CpG ODN to activate B cells and cooperate with B cell antigen receptor signaling, this paper reports a remarkably efficient method for generating human monoclonal antibodies.
  Article CAS PubMed Google Scholar
• Poeck, H. et al. Plasmacytoid dendritic cells, antigen and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T cell help. Blood 103, 3058–3064 (2004).
  Article CAS PubMed Google Scholar
• Krieg, A. M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).
  Article CAS PubMed Google Scholar
• Yi, A. K. et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160, 4755–4761 (1998).
  CAS PubMed Google Scholar
• Ahmad-Nejad, P. et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32, 1958–1968 (2002).
  Article CAS PubMed Google Scholar
• Hacker, H. et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17, 6230–6240 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Manzel, L., Strekowski, L., Ismail, F. M., Smith, J. C. & Macfarlane, D. E. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies. J Pharmacol. Exp. Ther. 291, 1337–1347 (1999).
  CAS PubMed Google Scholar
• Ishii, K. J. et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 196, 269–274 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Hacker, H. et al. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J. Exp. Med. 192, 595–600 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Schnare, M., Holtdagger, A. C., Takeda, K., Akira, S. & Medzhitov, R. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr. Biol. 10, 1139–1142 (2000).
  Article CAS PubMed Google Scholar
• Muzio, M., Ni, J., Feng, P. & Dixit, V. M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278, 1612–1615 (1997).
  Article CAS PubMed Google Scholar
• Muzio, M., Natoli, G., Saccani, S., Levrero, M. & Mantovani, A. The human toll signaling pathway: divergence of nuclear factor κB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 187, 2097–2101 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Rutz, M. et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 34, 2541–2550 (2004). Direct binding of TLR9 to CpG ODN has been reported by several groups but is still poorly understood. These investigators report binding to be at least partly sequence-specific under the low-pH conditions present in the endosome.
  Article CAS PubMed Google Scholar
• Hartmann, G. & Krieg, A. M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164, 944–953 (2000).
  Article CAS PubMed Google Scholar
• Yi, A. K. & Krieg, A. M. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J. Immunol. 161, 4493–4497 (1998).
  CAS PubMed Google Scholar
• Takeshita, F. & Klinman, D. M. CpG ODN-mediated regulation of IL-12 p40 transcription. Eur. J. Immunol. 30, 1967–1976 (2000).
  Article CAS PubMed Google Scholar
• Tsujimura, H. et al. Toll-like receptor 9 signaling activates NF-κB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J. Immunol. 172, 6820–6827 (2004).
  Article CAS PubMed Google Scholar
• Choudhury, B. K. et al. In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J. Immunol. 169, 5955–5961 (2002).
  Article CAS PubMed Google Scholar
• Yi, A. K., Yoon, J. G. & Krieg, A. M. Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N- terminal kinase and NF-κB activation pathways: regulation by mitogen-activated protein kinases. Int. Immunol. 15, 577–591 (2003).
  Article CAS PubMed Google Scholar
• Yi, A. K. et al. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J. Immunol. 168, 4711–4720 (2002).
  Article CAS PubMed Google Scholar
• Rankin, R. et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11, 333–340 (2001).
  Article CAS PubMed Google Scholar
• Yi, A. K., Chang, M., Peckham, D. W., Krieg, A. M. & Ashman, R. F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160, 5898–5906 (1998).
  CAS PubMed Google Scholar
• Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98, 9237–9242 (2001). The first paper showing a direct and species-specific interaction between TLR9 and different CpG motifs.
  Article CAS PubMed PubMed Central Google Scholar
• Latz, E. et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nature Immunol. 5, 190–198 (2004). A major advance in providing the clearest understanding yet into the intracellular trafficking of TLR9, and its response to CpG ODN.
  Article CAS Google Scholar
• Ballas, Z. K., Rasmussen, W. L. & Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157, 1840–1845 (1996).
  CAS PubMed Google Scholar
• Hartmann, G. et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164, 1617–1624 (2000).
  Article CAS PubMed Google Scholar
• Pisetsky, D. S. & Reich, C. F., III. The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology 40, 199–208 (1998).
  Article CAS PubMed Google Scholar
• Roberts, T. L., Sweet, M. J., Hume, D. A. & Stacey, K. J. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J. Immunol. 174, 605–608 (2005).
  Article CAS PubMed Google Scholar
• Vollmer, J. et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 113, 212–223 (2004). TLR9 can respond to more than CpG; this paper demonstrates that some CpG-free ODN can activate TLR9, but induce a distinct profile of cytokine production, revealing an unexpected plasticity in TLR9 biology.
  Article CAS PubMed PubMed Central Google Scholar
• Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251–262 (2004). Together with references 196 and 197 these three papers define the third class of CpG ODN, based on unique structural characteristics.
  Article CAS PubMed Google Scholar
• Hemmi, H., Kaisho, T., Takeda, K. & Akira, S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. 170, 3059–3064 (2003).
  Article CAS PubMed Google Scholar
• Honda, K. et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434, 1035–1040 (2005). This paper provides intriguing evidence that ODN structures with different biological properties have distinct intracellular distribution.
  Article CAS PubMed Google Scholar
• Uhlmann, E. & Vollmer, J. Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Discov. Devel. 6, 204–217 (2003).
  CAS PubMed Google Scholar
• Kandimalla, E. R., Zhu, F. G., Bhagat, L., Yu, D. & Agrawal, S. Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs. Biochem. Soc. Trans. 31, 654–658 (2003).
  Article CAS PubMed Google Scholar
• Krieg, A. M., Guga, P. & Stec, W. P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides 13, 491–499 (2003).
  Article CAS PubMed Google Scholar
• Krieg, A. M. et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl Acad. Sci. USA 95, 12631–12636 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Yamada, H. et al. Effect of suppressive DNA on CpG-induced immune activation. J. Immunol. 169, 5590–5594 (2002).
  Article CAS PubMed Google Scholar
• Lenert, P., Stunz, L. L., Yi, A. K., Krieg, A. M. & Ashman, R. F. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kB activation. Antisense Nucleic Acid Drug Dev. 11, 247–256 (2001).
  Article CAS PubMed Google Scholar
• Jurk, M. Selective inhibition of Toll-like receptor-mediated signalling by inhibitory oligodeoxynucleotides. Clin. Invest. Med. 27, 2333 (2005).
  Google Scholar
• Beignon, A. S. et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 15, 3265–3275 (2005).
  Article CAS Google Scholar
• Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131–1139 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Shirota, H., Gursel, M. & Klinman, D. M. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-γ- and IL-12-mediated signaling. J. Immunol. 173, 5002–5007 (2004).
  Article CAS PubMed Google Scholar
• Lenert, P., Rasmussen, W., Ashman, R. F. & Ballas, Z. K. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol. 22, 621–631 (2003).
  Article CAS PubMed Google Scholar
• Geary, R. S. et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25, 1272–1281 (1997).
  CAS PubMed Google Scholar
• Levin, A. A., Henry, S. & Monteith, D. Antisense Drug Technology (ed. Crooke, S. T.) 201–267 (Marcel Dekker, New York, 2001).
  Google Scholar
• Krieg, A. M., Efler, S. M., Wittpoth, M., Al Adhami, M. J. & Davis, H. L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 27, 460–471 (2004).
  Article CAS PubMed Google Scholar
• Elkins, K. L., Rhinehart-Jones, T. R., Stibitz, S., Conover, J. S. & Klinman, D. M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162, 2291–2298 (1999).
  CAS PubMed Google Scholar
• Gramzinski, R. A. et al. Interleukin-12- and γ interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect. Immun. 69, 1643–1649 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Zimmermann, S. et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160, 3627–3630 (1998).
  CAS PubMed Google Scholar
• Krieg, A. M., Love-Homan, L., Yi, A. K. & Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161, 2428–2434 (1998).
  CAS PubMed Google Scholar
• Klinman, D. M., Conover, J. & Coban, C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 67, 5658–5663 (1999).
  CAS PubMed PubMed Central Google Scholar
• Klinman, D. M., Verthelyi, D., Takeshita, F. & Ishii, K. J. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity 11, 123–129 (1999).
  Article CAS PubMed Google Scholar
• Rees, D. G. et al. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res. 65, 87–95 (2005).
  Article CAS PubMed Google Scholar
• Deng, J. C. et al. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J. Immunol. 173, 5148–5155 (2004).
  Article CAS PubMed Google Scholar
• Ray, N. B. & Krieg, A. M. Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. Infect. Immun. 71, 4398–4404 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Rev. Immunol. 4, 249–259 (2004).
  Article CAS Google Scholar
• Weighardt, H. et al. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J. Immunol. 165, 4537–4543 (2000).
  Article CAS PubMed Google Scholar
• Pyles, R. B. et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J. Virol. 76, 11387–11396 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ashkar, A. A., Bauer, S., Mitchell, W. J., Vieira, J. & Rosenthal, K. L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77, 8948–8956 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Walker, P. S. et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms. Proc. Natl Acad. Sci. USA 96, 6970–6975 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Cho, J. Y. et al. Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J. Allergy Clin. Immunol. 108, 697–702 (2001).
  Article CAS PubMed Google Scholar
• Juffermans, N. P. et al. CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect. Immun. 70, 147–152 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Olbrich, A. R. et al. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J. Virol. 76, 11397–11404 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Freidag, B. L. et al. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun. 68, 2948–2953 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Ramirez-Pineda, J. R., Frohlich, A., Berberich, C. & Moll, H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J. Immunol. 172, 6281–6289 (2004).
  Article CAS PubMed Google Scholar
• Ishii, K. J. et al. CpG-activated Thy1.2+ dendritic cells protect against lethal Listeria monocytogenes infection. Eur. J. Immunol. 35, 2397–2405 (2005).
  Article CAS PubMed Google Scholar
• Lugo-Villarino, G., Ito, S., Klinman, D. M. & Glimcher, L. H. The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells. Proc. Natl Acad. Sci. USA 102, 13248–13253 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Sajic, D. et al. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med. Virol. 71, 561–568 (2003).
  Article CAS PubMed Google Scholar
• Isogawa, M., Robek, M. D., Furuichi, Y. & Chisari, F. V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79, 7269–7272 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Verthelyi, D. et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 170, 4717–4723 (2003).
  Article CAS PubMed Google Scholar
• Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 5, 215–229 (2005).
  Article CAS Google Scholar
• McHutchison, J. G. et al. Relationships of HCV RNA responses to CPG 10101, a TLR9 agonist: pharmacodynamics &patient characteristics. Hepatology 42, 249A (2005).
  Google Scholar
• Olbrich, A. R., Schimmer, S. & Dittmer, U. Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J. Virol. 77, 10658–10662 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ito, S., Pedras-Vasconcelos, J. & Klinman, D. M. CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect. Immun. 73, 6154–6156 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Equils, O. et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-Long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170, 5159–5164 (2003).
  Article CAS PubMed Google Scholar
• Agrawal, S. and Martin, R. R. Was induction of HIV1 through TLR9? J. Immunol. 171, 1621 (2003).
  Article CAS PubMed Google Scholar
• Gurney, K. B., Colantonio, A. D., Blom, B., Spits, H. & Uittenbogaart, C. H. Endogenous IFN-α production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J. Immunol. 173, 7269–7276 (2004).
  Article CAS PubMed Google Scholar
• Schlaepfer, E. et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J. Virol. 78, 12344–12354 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Saez, R., Echaniz, P., de Juan, M. D., Iribarren, J. A. & Cuadrado, E. HIV-infected progressors and long-term non-progressors differ in their capacity to respond to an A-class CpG oligodeoxynucleotide. AIDS 19, 1924–1925 (2005).
  Article CAS PubMed Google Scholar
• Cooper, C. L. et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19, 1473–1479 (2005). In this clinical trial a TLR9 agonist was shown to have strong vaccine adjuvant activity even in immune-compromised (HIV-infected) humans, extending the results of vaccine trials in normal volunteers (references 129 and 130).
  Article CAS PubMed Google Scholar
• Davis, H. L. et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870–876 (1998).
  CAS PubMed Google Scholar
• Liu, N., Ohnishi, N., Ni, L., Akira, S. & Bacon, K. B. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nature Immunol. 4, 687–693 (2003).
  Article CAS Google Scholar
• He, B., Qiao, X. & Cerutti, A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J. Immunol. 173, 4479–4491 (2004).
  Article CAS PubMed Google Scholar
• Lipford, G. B., Sparwasser, T., Zimmermann, S., Heeg, K. & Wagner, H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol. 165, 1228–1235 (2000).
  Article CAS PubMed Google Scholar
• Sparwasser, T., Vabulas, R. M., Villmow, B., Lipford, G. B. & Wagner, H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 30, 3591–3597 (2000).
  Article CAS PubMed Google Scholar
• Tighe, H. et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30, 1939–1947 (2000).
  Article CAS PubMed Google Scholar
• Hartmann, E. et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63, 6478–6487 (2003). This report shows that CpG responses are severely suppressed in dendritic cells isolated from primary human tumours, but less so in the draining lymph nodes.
  CAS PubMed Google Scholar
• Wettstein, P. J., Borson, N. D., Park, J. G., McNallan, K. T. & Reed, A. M. Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses. J. Immunol. 175, 3681–3689 (2005).
  Article CAS PubMed Google Scholar
• Kim, S. K. et al. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 18, 597–603 (2000).
  Article Google Scholar
• Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. & Harding, C. V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623–1631 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Lipford, G. B. et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27, 2340–2344 (1997).
  Article CAS PubMed Google Scholar
• Roman, M. et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants [see comments]. Nature Med. 3, 849–854 (1997).
  Article CAS PubMed Google Scholar
• Weeratna, R. D., McCluskie, M. J., Xu, Y. & Davis, H. L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18, 1755–1762 (2000).
  Article CAS PubMed Google Scholar
• Sugai, T. et al. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23, 5450–5456 (2005).
  Article CAS PubMed Google Scholar
• Oumouna, M., Mapletoft, J. W., Karvonen, B. C., Babiuk, L. A. & van Drunen Littel-van den Hurk . Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J. Virol. 79, 2024–2032 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Brazolot Millan, C. L., Weeratna, R., Krieg, A. M., Siegrist, C. A. & Davis, H. L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA 95, 15553–15558 (1998).
  Article CAS PubMed Google Scholar
• Weeratna, R. D., Brazolot Millan, C. L., McCluskie, M. J., Siegrist, C. A. & Davis, H. L. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol. Med. Microbiol. 30, 241–247 (2001).
  Article CAS PubMed Google Scholar
• Schirmbeck, R. & Reimann, J. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 44, 115–123 (2001).
  Article CAS PubMed Google Scholar
• Zhou, X., Zheng, L., Liu, L., Xiang, L. & Yuan, Z. T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides. Scand. J. Immunol. 58, 350–357 (2003).
  Article CAS PubMed Google Scholar
• Weeratna, R. D., Brazolot Millan, C. L., McCluskie, M. J. & Davis, H. L. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol. Med. Microbiol. 32, 65–71 (2001).
  Article CAS PubMed Google Scholar
• Manning, B. M., Enioutina, E. Y., Visic, D. M., Knudson, A. D. & Daynes, R. A. CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp. Gerontol. 37, 107–126 (2001).
  Article CAS PubMed Google Scholar
• Maletto, B., Ropolo, A., Moron, V. & Pistoresi-Palencia, M. C. CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice. J. Leukoc. Biol. 72, 447–454 (2002).
  CAS PubMed Google Scholar
• Alignani, D. et al. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J. Leukoc. Biol. 77, 898–905 2005.
  Article CAS PubMed Google Scholar
• Krieg, A. M. & Davis, H. L. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3, 15–24 (2001).
  CAS PubMed Google Scholar
• Moldoveanu, Z., Love-Homan, L., Huang, W. Q. & Krieg, A. M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216–1224 (1998).
  Article CAS PubMed Google Scholar
• Gallichan, W. S. et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus- 2 in the genital tract. J. Immunol. 166, 3451–3457 (2001).
  Article CAS PubMed Google Scholar
• McCluskie, M. J. & Davis, H. L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161, 4463–4466 (1998).
  CAS PubMed Google Scholar
• McCluskie, M. J. & Davis, H. L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19, 413–422 (2001).
  Article Google Scholar
• Kwant, A. & Rosenthal, K. L. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22, 3098–3104 (2004).
  Article CAS PubMed Google Scholar
• Eastcott, J. W. et al. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19, 1636–1642 (2001).
  Article CAS PubMed Google Scholar
• McCluskie, M. J., Weeratna, R. D., Krieg, A. M. & Davis, H. L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19, 950–957 (2001).
  Article Google Scholar
• Dong, J. L., Liang, B. G., Jin, Y. S., Zhang, W. J. & Wang, T. Oral immunization with pBsVP6-transgenic alfalfa protects mice against rotavirus infection. Virology 339, 153–163 (2005).
  Article CAS PubMed Google Scholar
• Nesburn, A. B. et al. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23, 873–883 (2005).
  Article CAS PubMed Google Scholar
• Berry, L. J. et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72, 1019–1028 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Dumais, N., Patrick, A., Moss, R. B., Davis, H. L. & Rosenthal, K. L. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J. Infect. Dis. 186, 1098–1105 (2002).
  Article CAS PubMed Google Scholar
• Cooper, C. L. et al. CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol. 24, 693–702 (2004).
  Article CAS PubMed Google Scholar
• Halperin, S. A. et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21, 2461–2467 (2003). References 129 and 130 show dramatic adjuvant activity of two different B-Class CpG ODN added to the hepatitis B surface antigen both alone and in combination with alum.
  Article CAS PubMed Google Scholar
• Siegrist, C. A. et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23, 615–622 (2004).
  Article CAS PubMed Google Scholar
• Rynkiewicz, D. et al. Marked enhancement of antibody response to anthrax vaccine adsorbed with CPG 7909 in healthy volunteers. Intersci. Conf. Antimicrob. Agents Chemother. Poster (2005).
• Weeratna, R., Comanita, L. & Davis, H. L. CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol. Cell Biol. 81, 59–62 (2003).
  Article CAS PubMed Google Scholar
• Cooper, C. L. et al. Safety and Immunogenicity of CpG 7909 Injection as an Adjuvant to Fluarix Influenza Vaccine. Vaccine 22, 3136–3143 (2004).
  Article CAS PubMed Google Scholar
• Kline, J. N. et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160, 2555–2559 (1998).
  CAS PubMed Google Scholar
• Jain, V. V. et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J. Allergy Clin. Immunol. 110, 867–872 (2002).
  Article CAS PubMed Google Scholar
• Creticos, P. S., Eiden, J. J. & et al. Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J. Allergy Clin. Immunol. 109, 742–743 (2002).
  Google Scholar
• Simons, F. E., Shikishima, Y., Van Nest, G., Eiden, J. J. & HayGlass, K. T. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113, 1144–1151 (2004). This clinical trial report demonstrates that the anti-allergic effects of CpG ODN are not limited to mice, but are also seen in humans.
  Article CAS PubMed Google Scholar
• van Ojik, H. et al. Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGA-3 protein in patients with MAGE-3 positive tumors. Ann. Oncol. 13, 157 (2002).
  Google Scholar
• Speiser, D. E. et al. Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739–746 (2005). This is the first human clinical trial report of a CpG ODN added to a cancer vaccine, and shows that patients receiving the vaccine made a strong CD8 T-cell response to the tumour antigen.
  Article CAS PubMed PubMed Central Google Scholar
• Jain, V. V. et al. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L1137–L1146 (2003).
  Article CAS PubMed Google Scholar
• Fanucchi, M. V. et al. Immunostimulatory oligonucleotides attenuate airways remodelling in allergic monkeys. Am. J. Respir. Crit. Care Med. 170, 1153–1157 (2004).
  Article PubMed Google Scholar
• Racila, D. M. & Kline, J. N. Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J. Allergy Clin. Immunol. 116, 1202–1205 (2005).
  Article CAS PubMed Google Scholar
• Hayashi, T. et al. Inhibition of experimental asthma by indoleamine 2, 3-dioxygenase. J. Clin. Invest. 114, 270–279 (2004). This detailed investigation into the mechanism of action of a CpG ODN in treating experimental asthma in a mouse model revealed new insights into the surprising anti-inflammatory role of TLR9 activation in the lung. See also references 175 and 176.
  Article CAS PubMed PubMed Central Google Scholar
• Krieg, A. M. Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6, 88–95 (2004).
  Article PubMed Google Scholar
• Link, B. et al. Oligodeoxynucleotide CPG 7909 Delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin's lymphoma. J. Immunother. (in the press).
• Friedberg, J. W. et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 105, 489–495 (2005).
  Article CAS PubMed Google Scholar
• Weigel, B. J., Rodeberg, D. A., Krieg, A. M. & Blazar, B. R. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9, 3105–3114 (2003).
  CAS PubMed Google Scholar
• Balsari, A. et al. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur. J. Cancer 40, 1275–1281 (2004).
  Article CAS PubMed Google Scholar
• Wang, X. S., Sheng, Z., Ruan, Y. B., Guang, Y. & Yang, M. L. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J. Gastroenterol. 11, 1220–1224 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Carson, W. E., III, Shapiro, C. L., Crespin, T. R., Thornton, L. M. & Andersen, B. L. Cellular immunity in breast cancer patients completing taxane treatment. Clin. Cancer Res. 10, 3401–3409 (2004).
  Article CAS PubMed Google Scholar
• Emens, L. A., Reilly, R. T. & Jaffee, E. M. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. Breast Dis. 20, 13–24 (2004).
  Article CAS PubMed Google Scholar
• Manegold, C., Leichman, G., Gravenor, D. & et al. Addition of PF-3512676 (CpG 7909) to a Taxane/Platinum regimen for first-line treatment of unresectable non-small cell lung cancer (NSCLC) improves objective response — Phase II clinical trial. Eur. J. Cancer 3 (Suppl.), 326 A1131 (2005).
  Google Scholar
• Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69–84 (1999).
  Article CAS PubMed Google Scholar
• Monteith, D. K. & Levin, A. A. Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol. Pathol. 27, 8–13 (1999).
  Article CAS PubMed Google Scholar
• Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D. K. & Levin, A. A. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 12, 383–393 (1997).
  CAS PubMed Google Scholar
• Cossum, P. A. et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181–1190 (1993).
  CAS PubMed Google Scholar
• Henry, S. P., Taylor, J., Midgley, L., Levin, A. A. & Kornbrust, D. J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7, 473–481 (1997).
  Article CAS PubMed Google Scholar
• Heikenwalder, M. et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nature Med. 10, 187–192 (2004).
  Article CAS PubMed Google Scholar
• Jason, T. L., Koropatnick, J. & Berg, R. W. Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 201, 66–83 (2004).
  Article CAS PubMed Google Scholar
• Sparwasser, T. et al. Bacterial DNA causes septic shock. Nature 386, 336–337 (1997).
  Article CAS PubMed Google Scholar
• Henry, S. P. et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Immunopharmacol. 2, 1657–1666 (2002).
  Article CAS PubMed Google Scholar
• Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J. & Agrawal, S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201–206 (1994).
  Article CAS PubMed Google Scholar
• Monteith, D. K. et al. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. 46, 365–375 (1998).
  CAS PubMed Google Scholar
• Henry, S. P., Novotny, W., Leeds, J., Auletta, C. & Kornbrust, D. J. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7, 503–510 (1997).
  Article CAS PubMed Google Scholar
• Sheehan, J. P. & Lan, H. C. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92, 1617–1625 (1998).
  CAS PubMed Google Scholar
• Krieg, A. M. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J. Clin. Immunol. 15, 284–292 (1995).
  Article CAS PubMed Google Scholar
• Hasegawa, K. & Hayashi, T. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice. Lupus 12, 838–845 (2003).
  Article CAS PubMed Google Scholar
• Ichikawa, H. T., Williams, L. P. & Segal, B. M. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169, 2781–2787 (2002).
  Article CAS PubMed Google Scholar
• Obermeier, F. et al. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur. J. Immunol. 32, 2084–2092 (2002).
  Article CAS PubMed Google Scholar
• Ronaghy, A. et al. Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J. Immunol. 168, 51–56 (2002).
  Article CAS PubMed Google Scholar
• Katakura, K. et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695–702 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Boccaccio, G. L., Mor, F. & Steinman, L. Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis. Int. Immunol. 11, 289–296 (1999).
  Article CAS PubMed Google Scholar
• Quintana, F. J., Rotem, A., Carmi, P. & Cohen, I. R. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J. Immunol. 165, 6148–6155 (2000).
  Article CAS PubMed Google Scholar
• Wingender, G. et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36, 12–20 (2006).
  Article CAS PubMed Google Scholar
• Mellor, A. L. et al. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2, 3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 175, 5601–5605 (2005). Together with reference 175, these studies reveal what seems to be an important counter-regulatory pathway that is induced by TLR9 agonists given systemically (intravenously) but not when the agonists are given via local routes. Further studies will be required to determine whether this effect is direct (as described by one of the investigators) or indirect (as reported by the other).
  Article CAS PubMed Google Scholar
• Chen, Y. et al. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. Int. Immunol. 13, 1013–1020 (2001).
  Article CAS PubMed Google Scholar
• Ioannou, Y. & Isenberg, D. A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43, 1431–1442 (2000).
  Article CAS PubMed Google Scholar
• Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603–607 (2002). This seminal paper provided the first evidence that chromatin can activate TLR9, potentially triggering autoimmunity, as explored in further experiments from these and other investigators (references 180–183). Together, these studies point to potential therapeutic applications for TLR antagonists, which have been confirmed in references 184 and 185.
  Article CAS PubMed Google Scholar
• Viglianti, G. A. et al. Activation of autoreactive B cells by CpG dsDNA. Immunity 19, 837–847 (2003).
  Article CAS PubMed Google Scholar
• Boule, M. W. et al. Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199, 1631–1640 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Christensen, S. R. et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202, 321–331 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Means, T. K. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115, 407–417 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Dong, L., Ito, S., Ishii, K. J. & Klinman, D. M. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 52, 651–658 (2005).
  Article CAS PubMed Google Scholar
• Dong, L., Ito, S., Ishii, K. J. & Klinman, D. M. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum. 50, 1686–1689 (2004).
  Article CAS PubMed Google Scholar
• Kawai, T. et al. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nature Immunol. 5, 1061–1068 (2004).
  Article CAS Google Scholar
• Uematsu, S. et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction. J. Exp. Med. 201, 915–923 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Yeo, S. J., Yoon, J. G. & Yi, A. K. Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: tumor necrosis factor-α receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling. J. Biol. Chem. 278, 40590–40600 (2003).
  Article CAS PubMed Google Scholar
• Yeo, S. J., Gravis, D., Yoon, J. G. & Yi, A. K. Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-κB and p38. J. Biol. Chem. 278, 22563–22573 (2003).
  Article CAS PubMed Google Scholar
• Honda, K. et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772–777 (2005).
  Article CAS PubMed Google Scholar
• Yang, K. et al. Human TLR-7-, -8-, and-9-mediated induction of IFN-α/β and-λ Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 23, 465–478 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, C. M., Deriaud, E., Leclerc, C. & Lo-Man, R. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 22, 467–477 (2005).
  Article CAS PubMed Google Scholar
• Kerkmann, M. et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-α induction by CpG-A in plasmacytoid dendritic cells. J. Biol. Chem. 280, 8086–8093 (2005).
  Article CAS PubMed Google Scholar
• Marshall, J. D. et al. Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells. Nucleic Acids Res. 31, 5122–5133 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Fearon, K. et al. A minimal human immunostimulatory CpG motif that potently induces IFN-γ and IFN-α production. Eur. J. Immunol. 33, 2114–2122 (2003).
  Article CAS PubMed Google Scholar
• Hartmann, G. et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33, 1633–1641 (2003).
  Article CAS PubMed Google Scholar
• Marshall, J. D. et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73, 781–792 (2003).
  Article CAS PubMed Google Scholar
• Kemp, T. J., Elzey, B. D. & Griffith, T. S. Plasmacytoid dendritic cell-derived IFN-α induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol. 171, 212–218 (2003).
  Article CAS PubMed Google Scholar
• Utaisincharoen, P. et al. CpG ODN enhances uptake of bacteria by mouse macrophages. Clin. Exp. Immunol. 132, 70–75 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Klinman, D. M. Use of CpG oligodeoxynucleotides as immunoprotective agents. Exp. Opin. Biol. Ther. 4, 937–946 (2004).
  Article CAS Google Scholar
• Efler, S. M., Zhang, L., Noll, B. O., Uhlmann, E. & Davis, H. L. Quantification of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis. Oligonucleotides 15, 119–131 (2005).
  Article CAS PubMed Google Scholar
• Krieg, A. M. & Davis, H. L. Vaccine Adjuvants: Immunological and Clinical Principles (eds Hackett, C. J. & Harn, Jr. D. A.) 87–110 (Humana, Totowa, 2006).
  Book Google Scholar
• Halperin, S. A. et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24, 20–26 (2006).
  Article CAS PubMed Google Scholar
• Lin, L., Gerth, A. J. & Peng, S. L. CpG DNA redirects class-switching towards 'Th1-like' Ig isotype production via TLR9 and MyD88. Eur. J. Immunol. 34, 1483–1487 (2004).
  Article CAS PubMed Google Scholar